Human CD30 Ligand/TNFSF8 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB7741
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, Immunohistochemistry, Neutralization
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2A Clone # 116632
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived human CD30 Ligand/TNFSF8.
Gln63-Asp234
Accession # P32971
Gln63-Asp234
Accession # P32971
Specificity
Detects human CD30 LIgand/TNFSF8 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human CD30 Ligand/TNFSF8 Antibody
Detection of CD30 Ligand/TNFSF8 in Human PBMC by Flow Cytometry.
Human PBMC either (A) Activated with PMA (50 ng/ml) and Ca2+ Ionomycin (200 ng/ml) for 16 hours, or (B) untreated, were stained with Mouse Anti-Human CD30 Ligand/TNFSF8 Monoclonal Antibody (Catalog # MAB7741) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (F0102B) and Mouse anti-Human CD3 APC-conjugated Monoclonal Antibody (FAB100A). Quadrant markers were set based on control antibody staining (MAB003). Staining was performed using our Staining Membrane-associated Proteins protocol.
CD30 Ligand/TNFSF8 in Human Spleen.
CD30 Ligand/TNFSF8 was detected in immersion fixed paraffin-embedded sections of human spleen using Mouse Anti-Human CD30 Ligand/TNFSF8 Monoclonal Antibody (Catalog # MAB7741) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody VC001. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic CTS013. Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell surface in splenic nodules. Staining was performed using our IHC Staining with our VisUCyte HRP Polymer Detection Reagents Protocol.
IL-6 Secretion Induced by CD30 Ligand/TNFSF8 and Neutralization by Human CD30 Ligand/TNFSF8 Antibody.
In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (10 µg/mL, MAB050), Recombinant Human CD30 Ligand/TNFSF8 (Catalog # Catalog # 1028-CL) stimulates IL-6 secretion in the HDLM human Hodgkin’s lymphoma cell line in a dose-dependent manner (orange line), as measured by the Human IL-6 Quantikine ELISA Kit (D6050). Under these conditions, IL-6 secretion elicited by Recombinant Human CD30 Ligand/TNFSF8 (1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CD30 Ligand/TNFSF8 Monoclonal Antibody (Catalog # MAB7741). The ND50 is typically 0.3-3 µg/mL.Applications for Human CD30 Ligand/TNFSF8 Antibody
Application
Recommended Usage
Flow Cytometry
0.25 µg/106 cells
Sample: Human PBMC activated with PMA (50 ng/ml) and Ca2+ Ionomycin (200 ng/ml) for 16 hours
Sample: Human PBMC activated with PMA (50 ng/ml) and Ca2+ Ionomycin (200 ng/ml) for 16 hours
Immunohistochemistry
5-25 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human spleen
Sample: Immersion fixed paraffin-embedded sections of human spleen
Neutralization
Measured by its ability to neutralize CD30 Ligand/TNFSF8-induced IL‑6 secretion in the HDLM human Hodgkin's lymphoma cell line. The Neutralization Dose (ND50) is typically 0.3-3 µg/mL in the presence of 1 µg/mL Recombinant Human CD30 Ligand/TNFSF8 and 10 µg/mL of a cross-linking antibody, Mouse Anti-His Tag Monoclonal Antibody.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD30 Ligand/TNFSF8
CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a co-stimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. Human and mouse CD30 ligand cDNAs share 70% sequence homology.
References
- Brunangelo, F. et al. (1995) Blood 85:1.
- Duckett, C.S. et al. (1997) Mol. Cell. Biol. 17:1535.
- Chiarle, R. et al. (1999) J. Immunol. 163:194.
Alternate Names
CD153, CD30L, TNFSF8
Gene Symbol
TNFSF8
UniProt
Additional CD30 Ligand/TNFSF8 Products
Product Documents for Human CD30 Ligand/TNFSF8 Antibody
Product Specific Notices for Human CD30 Ligand/TNFSF8 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...